Mirum Pharmaceuticals (MIRM) Change in Receivables (2022 - 2026)

Mirum Pharmaceuticals' Change in Receivables history runs 5 years deep, the most recent figure standing at $12.9 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 23.45% year-over-year to $12.9 million; the TTM figure through Mar 2026 stood at $44.1 million (up 6.99% YoY), while the FY2025 annual figure was $48.1 million, up 320.58% from the prior year.
• Change in Receivables for Q1 2026 stood at $12.9 million, down from $19.0 million in the prior quarter.
• The five-year high for Change in Receivables was $20.1 million in Q4 2023, with the low at -$13.0 million in Q1 2024.
• The 5-year median for Change in Receivables is $8.1 million (2024), against an average of $8.1 million.
• The sharpest annual moves came in 2023 and 2024: Change in Receivables soared 432.94% in 2023, then tumbled 2044.38% in 2024.
• Mirum Pharmaceuticals' Change in Receivables stood at $7.7 million in 2022, then surged by 162.95% to $20.1 million in 2023, then plunged by 46.04% to $10.9 million in 2024, then jumped by 74.96% to $19.0 million in 2025, then tumbled by 32.21% to $12.9 million in 2026.
• Business Quant data shows MIRM's Change in Receivables at $12.9 million in Q1 2026, $19.0 million in Q4 2025, and $3.1 million in Q3 2025.